Pacira BioSciences Announces Board Election Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Source: PRnewswire
- Board Election Results: Preliminary results indicate that all three of Pacira's director nominees, Christopher Christie, Samit Hirawat, and Thomas Wiggans, were elected to the Board, reflecting shareholder confidence in the company's future direction.
- Management's Gratitude: CEO Frank D. Lee expressed appreciation to shareholders, emphasizing the commitment to executing the 5x30 strategy to drive long-term value and maintain positive momentum moving forward.
- Independent Election Oversight: The election results will be finalized and certified by an independent inspector of elections, with a report to be filed on Form 8-K with the SEC, ensuring transparency and compliance.
- Innovative Pain Therapies: Pacira focuses on non-opioid pain management with three commercial products, including EXPAREL, ZILRETTA, and iovera, aiming to enhance patient quality of life and expand market share.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PCRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PCRX
Wall Street analysts forecast PCRX stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 23.360
Low
23.00
Averages
30.33
High
38.00
Current: 23.360
Low
23.00
Averages
30.33
High
38.00
About PCRX
Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pacira BioSciences Announces Board Election Results
- Board Election Results: Preliminary results indicate that all three of Pacira's director nominees, Christopher Christie, Samit Hirawat, and Thomas Wiggans, were elected to the Board, reflecting shareholder confidence in the company's future direction.
- Management's Gratitude: CEO Frank D. Lee expressed appreciation to shareholders, emphasizing the commitment to executing the 5x30 strategy to drive long-term value and maintain positive momentum moving forward.
- Independent Election Oversight: The election results will be finalized and certified by an independent inspector of elections, with a report to be filed on Form 8-K with the SEC, ensuring transparency and compliance.
- Innovative Pain Therapies: Pacira focuses on non-opioid pain management with three commercial products, including EXPAREL, ZILRETTA, and iovera, aiming to enhance patient quality of life and expand market share.
See More
Pacira BioSciences Announces Board Election Results
- Successful Board Election: Preliminary results indicate that all three of Pacira's director nominees, Christopher Christie, Samit Hirawat, and Thomas Wiggans, were elected, reflecting shareholder confidence in the company's future direction.
- Management's Gratitude: CEO Frank D. Lee expressed appreciation to shareholders, emphasizing the commitment to continue executing the 5x30 strategy to drive long-term value and ensure the company maintains its positive momentum moving forward.
- Election Results Pending Confirmation: The results are preliminary, with final results to be tabulated and certified by an independent inspector of elections, to be reported in a Current Report on Form 8-K filed with the SEC, ensuring transparency and compliance.
- Advisory Support: Pacira has engaged Goldman Sachs as its financial advisor and Perkins Coie LLP as legal counsel, highlighting the company's focus on governance and compliance to enhance investor confidence.
See More
Pacira Urges Shareholders to Support Director Nominees
- Importance of Voting: Pacira BioSciences emphasizes the need for shareholders to vote 'FOR' its three director nominees at the Annual Meeting on June 9, 2026, to safeguard the company's strong growth momentum under its 5x30 strategy, thereby enhancing long-term shareholder value.
- Independent Expert Endorsements: Leading proxy advisory firms ISS, Glass Lewis, and Egan-Jones unanimously support Pacira's board and management team, recommending shareholders vote 'FOR' Pacira's nominees and 'AGAINST' those from DOMA, which is crucial for maintaining the company's long-term growth and value creation.
- Market Position in Non-Opioid Therapies: Pacira focuses on innovative non-opioid pain therapies with three commercial products—EXPAREL, ZILRETTA, and iovera®—and is expected to further solidify its leadership in pain management through ongoing clinical pipelines and market expansion.
- Streamlined Proxy Voting Process: Pacira encourages shareholders to vote via the blue proxy card or through online, telephone, and mail options, ensuring every shareholder's voice is heard while avoiding disruption from DOMA's short-term agenda, thus protecting the future investment value of the company.
See More
Pacira Urges Shareholders to Support Director Nominations
- Importance of Shareholder Vote: Pacira reminds shareholders to vote 'FOR' its three director nominees at the June 9, 2026 Annual Meeting to safeguard the company's leadership in non-opioid pain management and ensure sustainable growth and long-term shareholder value.
- Record Financial Performance: In 2025, Pacira achieved a record total revenue of $726.4 million with a GAAP gross margin of 79.4%, and in Q1 2026, EXPAREL revenue reached $143.3 million, a 5% year-over-year increase, reflecting strong commercial execution and market demand.
- Strategic Execution and Governance: Pacira's 5x30 strategy has driven growth across its commercial portfolio and ongoing advancement of its pipeline, with independent third-party firms like ISS and Glass Lewis recommending shareholders support Pacira's nominees, highlighting effective governance.
- Opposition to DOMA Nominations: Pacira warns shareholders that DOMA's nominees lack relevant experience and could disrupt the company's growth trajectory, urging shareholders to vote against DOMA's nominees to protect innovation investments and long-term value.
See More
Pacira Receives ISS Support for Management Nominees
- Management Nominee Support: Independent proxy advisory firm ISS recommends that Pacira shareholders vote for the three management nominees at the 2026 Annual Meeting, reflecting confidence in the company's governance and strategic direction, which could enhance shareholder trust and boost stock prices.
- Strategic Execution Impact: ISS noted that Pacira's performance has measurably improved following the implementation of its 5x30 shareholder value creation strategy, indicating that the company can effectively navigate market challenges and drive long-term growth under proactive management and board guidance.
- Board Composition Advantage: The Pacira board comprises seven newly appointed or nominated directors with extensive experience in relevant industries and corporate governance, enhancing decision-making capabilities during the company's turnaround phase and increasing shareholder confidence in future prospects.
- Opposition to Dissident Nominees: ISS criticized DOMA's nominees for lacking public company board experience and failing to present a compelling case for change, emphasizing the stability and strategic alignment of Pacira's existing board, which may help maintain operational continuity and market competitiveness.
See More
ISS Recommends Support for Pacira Management Nominees
- Support for Management Nominees: Institutional Shareholder Services (ISS) recommends that Pacira stockholders vote 'FOR' the management's three director nominees at the 2026 Annual Meeting, reflecting confidence in the company's governance structure and likely enhancing shareholder support for future developments.
- Significant Strategic Execution: Following the implementation of its 5x30 strategy, Pacira has seen measurable performance improvements, indicating that the company's efforts in shareholder value creation are recognized, which may attract more investor interest in its long-term growth potential.
- Board Composition Advantage: ISS emphasizes that Pacira's board consists of highly qualified directors with relevant industry and corporate governance experience, showcasing the company's leadership and strategic direction strengths, which could enhance market trust.
- Opposition to DOMA Nominees: ISS notes that DOMA's nominees lack credibility and fail to present a compelling case for change, which may lead to diminished shareholder confidence in their proposals, thereby solidifying the position of Pacira's current management team.
See More
Pacira BioSciences Announces Board Election Results
- Board Election Results: Preliminary results indicate that all three of Pacira's director nominees, Christopher Christie, Samit Hirawat, and Thomas Wiggans, were elected to the Board, reflecting shareholder confidence in the company's future direction.
- Management's Gratitude: CEO Frank D. Lee expressed appreciation to shareholders, emphasizing the commitment to executing the 5x30 strategy to drive long-term value and maintain positive momentum moving forward.
- Independent Election Oversight: The election results will be finalized and certified by an independent inspector of elections, with a report to be filed on Form 8-K with the SEC, ensuring transparency and compliance.
- Innovative Pain Therapies: Pacira focuses on non-opioid pain management with three commercial products, including EXPAREL, ZILRETTA, and iovera, aiming to enhance patient quality of life and expand market share.
See More
Pacira BioSciences Announces Board Election Results
- Successful Board Election: Preliminary results indicate that all three of Pacira's director nominees, Christopher Christie, Samit Hirawat, and Thomas Wiggans, were elected, reflecting shareholder confidence in the company's future direction.
- Management's Gratitude: CEO Frank D. Lee expressed appreciation to shareholders, emphasizing the commitment to continue executing the 5x30 strategy to drive long-term value and ensure the company maintains its positive momentum moving forward.
- Election Results Pending Confirmation: The results are preliminary, with final results to be tabulated and certified by an independent inspector of elections, to be reported in a Current Report on Form 8-K filed with the SEC, ensuring transparency and compliance.
- Advisory Support: Pacira has engaged Goldman Sachs as its financial advisor and Perkins Coie LLP as legal counsel, highlighting the company's focus on governance and compliance to enhance investor confidence.
See More
Pacira Urges Shareholders to Support Director Nominees
- Importance of Voting: Pacira BioSciences emphasizes the need for shareholders to vote 'FOR' its three director nominees at the Annual Meeting on June 9, 2026, to safeguard the company's strong growth momentum under its 5x30 strategy, thereby enhancing long-term shareholder value.
- Independent Expert Endorsements: Leading proxy advisory firms ISS, Glass Lewis, and Egan-Jones unanimously support Pacira's board and management team, recommending shareholders vote 'FOR' Pacira's nominees and 'AGAINST' those from DOMA, which is crucial for maintaining the company's long-term growth and value creation.
- Market Position in Non-Opioid Therapies: Pacira focuses on innovative non-opioid pain therapies with three commercial products—EXPAREL, ZILRETTA, and iovera®—and is expected to further solidify its leadership in pain management through ongoing clinical pipelines and market expansion.
- Streamlined Proxy Voting Process: Pacira encourages shareholders to vote via the blue proxy card or through online, telephone, and mail options, ensuring every shareholder's voice is heard while avoiding disruption from DOMA's short-term agenda, thus protecting the future investment value of the company.
See More
Pacira Urges Shareholders to Support Director Nominations
- Importance of Shareholder Vote: Pacira reminds shareholders to vote 'FOR' its three director nominees at the June 9, 2026 Annual Meeting to safeguard the company's leadership in non-opioid pain management and ensure sustainable growth and long-term shareholder value.
- Record Financial Performance: In 2025, Pacira achieved a record total revenue of $726.4 million with a GAAP gross margin of 79.4%, and in Q1 2026, EXPAREL revenue reached $143.3 million, a 5% year-over-year increase, reflecting strong commercial execution and market demand.
- Strategic Execution and Governance: Pacira's 5x30 strategy has driven growth across its commercial portfolio and ongoing advancement of its pipeline, with independent third-party firms like ISS and Glass Lewis recommending shareholders support Pacira's nominees, highlighting effective governance.
- Opposition to DOMA Nominations: Pacira warns shareholders that DOMA's nominees lack relevant experience and could disrupt the company's growth trajectory, urging shareholders to vote against DOMA's nominees to protect innovation investments and long-term value.
See More
Pacira Receives ISS Support for Management Nominees
- Management Nominee Support: Independent proxy advisory firm ISS recommends that Pacira shareholders vote for the three management nominees at the 2026 Annual Meeting, reflecting confidence in the company's governance and strategic direction, which could enhance shareholder trust and boost stock prices.
- Strategic Execution Impact: ISS noted that Pacira's performance has measurably improved following the implementation of its 5x30 shareholder value creation strategy, indicating that the company can effectively navigate market challenges and drive long-term growth under proactive management and board guidance.
- Board Composition Advantage: The Pacira board comprises seven newly appointed or nominated directors with extensive experience in relevant industries and corporate governance, enhancing decision-making capabilities during the company's turnaround phase and increasing shareholder confidence in future prospects.
- Opposition to Dissident Nominees: ISS criticized DOMA's nominees for lacking public company board experience and failing to present a compelling case for change, emphasizing the stability and strategic alignment of Pacira's existing board, which may help maintain operational continuity and market competitiveness.
See More
ISS Recommends Support for Pacira Management Nominees
- Support for Management Nominees: Institutional Shareholder Services (ISS) recommends that Pacira stockholders vote 'FOR' the management's three director nominees at the 2026 Annual Meeting, reflecting confidence in the company's governance structure and likely enhancing shareholder support for future developments.
- Significant Strategic Execution: Following the implementation of its 5x30 strategy, Pacira has seen measurable performance improvements, indicating that the company's efforts in shareholder value creation are recognized, which may attract more investor interest in its long-term growth potential.
- Board Composition Advantage: ISS emphasizes that Pacira's board consists of highly qualified directors with relevant industry and corporate governance experience, showcasing the company's leadership and strategic direction strengths, which could enhance market trust.
- Opposition to DOMA Nominees: ISS notes that DOMA's nominees lack credibility and fail to present a compelling case for change, which may lead to diminished shareholder confidence in their proposals, thereby solidifying the position of Pacira's current management team.
See More
